Figure 3From: Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study Kaplan-Meier estimates of overall survival. The median survival was 19.9 months (95% CI (11.9, 26.2)) in the Capecitabine 1750 mg/m2 group and 15.9 months (95% CI (13.1, 27.7)) in the capecitabine 1500 mg/m2 group.Back to article page